SCHEMBL16212100

SCHEMBL16212100

CC1CN(C(=O)O)CC1=O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21081462 0.79 LMNA (0.35)
SCHEMBL504706 0.79 LMNA (0.35)
SCHEMBL22634130 0.79 LMNA (0.35)
SCHEMBL6032147 0.77 MAPT (0.31)
SCHEMBL20898714 0.77 MAPT (0.31)
SCHEMBL1922221 0.77 MAPT (0.31)
SCHEMBL1705283 0.75
SCHEMBL29155813 0.75 ALDH1A1 (0.43)
SCHEMBL7455213 0.74 ITGB3 (0.31)
SCHEMBL27701469 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11129832-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2021-09-28 US disclosed
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-06-18 US disclosed
CN-105431420-B Diheteroaryl compounds and uses thereof 豪夫迈·罗氏有限公司 2019-08-13 CN disclosed
CN-110003178-A Two heteroaryl compounds and application thereof 豪夫迈·罗氏有限公司 2019-07-12 CN disclosed
US-10010549-B2 Biheteroaryl compounds and uses thereof GENENTECH, INC. (US) 2018-07-03 US disclosed
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2018-05-17 US disclosed
CN-105431420-A Diheteroaryl compounds and uses thereof HOFFMANN LA ROCHE 2016-03-23 CN disclosed
EP-2991978-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF F. Hoffmann-La Roche SA (CH) 2016-03-09 EP disclosed
US-20160052940-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-02-25 US disclosed
WO-2014177060-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF F.HOFFMANN-LA ROCHE AG (CH) 2014-11-06 WO disclosed
CN-101094846-A 1- (hetero) aryl-3-amino-pyrrolidine derivatives as MGLUR3 receptor antagonists LILLY CO ELI (US) 2007-12-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10010549-B2 Biheteroaryl compounds and uses thereof BCHE, SNCA, HAX1 NOTUM 4396/4885
US-11129832-B2 Biheteroaryl compounds and uses thereof BCHE, SNCA, HAX1 NOTUM 4396/4885
US-20180133219-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 NOTUM 4396/4885
US-20160052940-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 NOTUM 4396/4885
US-20200188397-A1 BIHETEROARYL COMPOUNDS AND USES THEREOF BCHE, SNCA, HAX1 NOTUM 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.